Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

FDA Gives Positive Review Of Aerie’s Experimental Glaucoma Drug

By Meagan Parrish | October 11, 2017

A study by the U.S. Food and Drug Administration has backed up Aerie Pharmaceutical’s evidence that its experimental drug is effective in treating glaucoma.

According to Reuters, the results were from a preliminary review, and the agency is still waiting on advice from outside experts. But upon news of the findings, Aerie’s shares jumped by 19 percent.

Glaucoma is often caused by a buildup of pressure inside the eye, which can damage the optic nerve and eventually cause permanent vision loss. In fact, it is the second leading cause of blindness around the world.

The number of Americans with glaucoma is expected to rise in the coming years. By 2030, an estimated 4 million Americans will have glaucoma — up from 2.7 million who have it now.

The drugs currently on the market that typically treat glaucoma are prostaglandins such as Pfizer’s Xalatan and Novartis AG’s Travatan. This class of drugs help lower eye pressure.

Aerie’s drug, called Rhopressa, is also designed to lower pressure but instead targets the main drain for eye fluid, called the trabecular network. The treatment is also supposed to have a lower risk of pigmentation and changes to eyelash length.

Rhopressa is a once-daily treatment; and the FDA also concluded that a double dose did not help those with a higher buildup of pressure.


Filed Under: Drug Discovery

 

Related Articles Read More >

EpicentRx
A next-gen vaccine that could help end COVID-19 whack-a-mole 
Dotmatics
How Dotmatics aims to help reduce the drug discovery failure rate
Diversity
Making diversity in clinical research more than a talking point
psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50